Stockwinners Market Radar for July 22, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:31 EDT Revelation Biosciences reports results from Phase 1b CLEAR study of REVTx-99b - Revelation Biosciences announced topline data for its Phase 1b CLEAR clinical study to evaluate the effect of intranasal REVTx-99b on nasal challenge allergen in participants with allergic rhinitis to rye grass pollen. The primary endpoint to evaluate the effects of REVTx-99b versus placebo on safety and tolerability was met. Exploratory endpoints for efficacy were not met. This includes no reduction in allergy symptoms and no increase in peak nasal inspiratory flow versus placebo. The study enrolled two cohorts: one cohort received study drug prior to nasal allergen challenge (the prophylactic cohort) and the second cohort received study drug after the nasal allergen challenge. The Phase 1b, randomized, double-blind, placebo-controlled, crossover study design was conducted in Australia. Revelation management plans to evaluate future development of this and other ongoing programs.

18:16 EDT Huntington Ingalls Shipbuilding awarded DDG design engineering contract - HII announced that its Ingalls Shipbuilding division has been awarded a cost-plus-incentive-fee contract for engineering and design from the U.S. Navy for the next-generation guided-missile destroyer program.

17:17 EDT MP Materials to replace Sanderson Farms in S&P 400 at open on 7/27 - Cargill and Continental Grain acquired Sanderson Farms in a deal that closed July 22.

16:13 EDT Four Corners Property Trust acquires Outback Steakhouse property for $2.4M - Four Corners Property Trust announced the acquisition of an Outback Steakhouse property for $2.4M. The property is located in a strong retail corridor in Indiana and is corporate-operated under a net lease with approximately four years of term remaining. The transaction was priced at a 6.8% going-in cash capitalization rate, exclusive of transaction costs.

16:05 EDT WWE CEO Vince McMahon retires - Vince McMahon released the following statement: "As I approach 77 years old, I feel it's time for me to retire as Chairman and CEO of WWE. Throughout the years, it's been a privilege to help WWE bring you joy, inspire you, thrill you, surprise you, and always entertain you. I would like to thank my family for mightily contributing to our success, and I would also like to thank all of our past and present Superstars and employees for their dedication and passion for our brand. Most importantly, I would like to thank our fans for allowing us into your homes every week and being your choice of entertainment. I hold the deepest appreciation and admiration for our generations of fans all over the world who have liked, currently like, and sometimes even love our form of Sports Entertainment. Our global audience can take comfort in knowing WWE will continue to entertain you with the same fervor, dedication, and passion as always. I am extremely confident in the continued success of WWE, and I leave our company in the capable hands of an extraordinary group of Superstars, employees, and executives - in particular, both Chairwoman and Co-CEO Stephanie McMahon and Co-CEO Nick Khan. As the majority shareholder, I will continue to support WWE in any way I can. My personal thanks to our community and business partners, shareholders, and Board of Directors for their guidance and support through the years. Then. Now. Forever. Together."

16:02 EDT Nicholas Financial extends employment agreement of CFO Nashtatik - Nicholas Financial announced the extension of Irina Nashtatik's employment agreement as CFO through June 30, 2024.

13:03 EDT Baker Hughes reports U.S. rig count up 2 to 758 rigs - Baker Hughes reports that the U.S. rig count is up 2 from last week to 758 with oil rigs unchanged at 599, gas rigs up 2 to 155 and miscellaneous rigs unchanged at 4. The U.S. Rig Count is up 267 rigs from last year's count of 491 with oil rigs up 212, gas rigs up 51 and miscellaneous rigs up 4. The U.S. Offshore Rig Count is up 2 to 16, down 1 year-over-year. The Canada Rig Count is up 4 from last week to 195, with oil rigs down 1 to 124, gas rigs up 5 to 71. The Canada Rig Count is up 46 rigs from last year's count of 149, with oil rigs up 31, gas rigs up 16 and miscellaneous rigs down 1.

12:38 EDT Getty Images, CC Neuberger Principal Holdings II complete combination - Getty Images and CC Neuberger Principal Holdings, a publicly traded special purpose acquisition company, announced the completion of their previously announced business combination. Upon completion of the business combination, the combined company has been renamed Getty Images Holdings, Inc. Beginning on July 25, 2022, the company's common stock and warrants are expected to begin trading on the New York Stock Exchange under the symbol "GETY." Craig Peters, CEO of Getty Images, said, "Getty Images moves the world with content that can't be found anywhere else." Mark Getty will continue to serve as Chairman, while Craig Peters will continue to lead Getty Images as CEO, along with the current Getty Images management team.

12:01 EDT Volkswagen announces CEO Diess to leave Board of Management - The Supervisory Board of Volkswagen AG and Dr. Herbert Diess have agreed today that Dr. Diess will leave the Board of Management of Volkswagen AG by mutual consent with effect as of September 1, 2022, the company announced. "Dr. Diess will be succeeded by Dr. Oliver Blume, Chairman of the Board of Management of Dr. Ing. h.c. F. Porsche AG. Dr. Oliver Blume will also remain Chairman of the Board of Management of Dr. Ing. h.c. F. Porsche AG. In today's meeting, the Supervisory Board also resolved that the CFO of Volkswagen AG, Dr. Arno Antlitz, will additionally assume the position as Chief Operating Officer and thus support Dr. Blume with day-to-day operations," Volkswagen stated.

12:00 EDT Vertical Aerospace falls -17.7% - Vertical Aerospace is down -17.7%, or -$1.43 to $6.64.

12:00 EDT Eve Holding rises 14.5% - Eve Holding is up 14.5%, or $1.04 to $8.23.

12:00 EDT AMTD Digital rises 26.0% - AMTD Digital is up 26.0%, or $5.28 to $25.59.

11:21 EDT Airbnb confirms hiring Jay Carney as Global Head of Policy - Airbnb (ABNB) announced that Jay Carney, Senior Vice President of Global Corporate Affairs at Amazon (AMZN) and former White House Press Secretary for President Barack Obama, is joining the company as Global Head of Policy and Communications. Carney will serve on Airbnb's executive team and work with co-founder and CEO Brian Chesky. Carney will start at Airbnb in September, reporting to co-founder and CEO Brian Chesky. Reference Link

10:53 EDT Cleveland-Cliffs: Dividend issuance 'not our priority'

10:50 EDT Mercer acquires Holzindustrie Torgau for EUR 270M - Mercer International announced that it has entered into an agreement to acquire all of the outstanding shares of the parent company of Holzindustrie Torgau, or HIT, for consideration of EUR 270M, inclusive of forecasted net working capital of approximately EUR 43M HIT owns 100% of a timber processing and value-add pallet production facility in Torgau, Germany and a wood processing facility in Dahlen, Germany that produces garden products. The transaction is subject to customary closing conditions, including receipt of requisite regulatory anti-trust approvals. It is expected to close in Q3 or Q4 of 2022. Mercer said, "We believe the acquisition of HIT and the integration of its facilities with our existing operations can generate operating synergies of approximately $16 million per year, realizable within six to twelve months of ownership, primarily through procurement opportunities, optimization of logistics / fiber and other cost benefits. Further, we believe there is an opportunity to optimize the HIT Facility to align it with our existing Friesau sawmill and improve their combined ability to produce lumber for the U.S. and European lumber markets." Mercer intends to satisfy payment of the purchase price using its existing cash on hand and/or revolving credit facilities.

10:40 EDT Cleveland-Cliffs: Construction demand starting to slow

10:30 EDT Eos Energy establishes 'Eos Ingenuity Lab' at Edison, NJ headquarters - Eos Energy Enterprises announced the dedication of the "Eos Ingenuity Lab," a site focused on expanding the company's R&D capacity as it designs future generations of its Znyth aqueous battery and forges a path toward rapid manufacturing and deployment of its energy storage systems. Located at Eos' corporate headquarters in Edison, NJ, the Eos Ingenuity Lab provides the space and resources to continue evolving Eos' safe, flexible zinc battery technology as part of the Company's mission to accelerate the shift to clean energy. A focus of the Lab will be to refine and optimize Eos' current technology while creating prototypes for future designs that can be tested under a variety of conditions. The current model has a wide operability range from 3 to 12 hour discharge durations. Development and testing of new modular containers to transport and house the batteries as well as advanced manufacturing processes will also be studied.

10:16 EDT VRAX Stock trading resumes

10:05 EDT Cleveland-Cliffs sees pricing in Q3 impacted by falling commodity index prices - Sees continued substantial increases in fixed contract prices in the upcoming renewal cycle. Comments taken from Q2 earnings conference call.

10:00 EDT Pinterest falls -8.6% - Pinterest is down -8.6%, or -$1.81 to $19.13.

10:00 EDT Snap falls -35.2% - Snap is down -35.2%, or -$5.76 to $10.59.

10:00 EDT Community Health rises 22.2% - Community Health is up 22.2%, or 91c to $5.02.

09:55 EDT EMA recommends restricting use of Clovis' Rubraca - The EMA's human medicines committee, CHMP, has recommended that Rubraca should no longer be used as third-line treatment for cancers of the ovary, fallopian tubes or peritoneum with a BRCA mutation in patients whose cancer has come back after at least two platinum-based chemotherapies and who cannot have further platinum-based therapy, the agency announced. "The recommendation follows the review of final data from the ARIEL4 study,1 which compared Rubraca with chemotherapy in patients whose cancer had come back after at least two previous treatments and who were still eligible for further chemotherapy. The final analysis of overall survival showed that Rubraca was not as effective as chemotherapy at prolonging patients' lives: those treated with Rubraca lived for an average of 19.4 months, compared with 25.4 months for patients receiving chemotherapy. As a result, doctors should not start third-line treatment with Rubraca in new patients. Doctors should inform patients already receiving Rubraca for this indication of the latest data and recommendations, and consider other treatment options," the EMA stated. Reference Link

09:47 EDT Pinterest falls -9.1% - Pinterest is down -9.1%, or -$1.90 to $19.04.

09:47 EDT Community Health rises 14.1% - Community Health is up 14.1%, or 58c to $4.69.

09:47 EDT Hanger rises 25.1% - Hanger is up 25.1%, or $3.70 to $18.45.

09:44 EDT Kite receives positive CHMP opinion for Tecartus for r/r ALL - Kite, a Gilead Company, announces that the European Medicines Agency Committee for Medicinal Products for Human Use has issued a positive opinion for Tecartus for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. If approved, Tecartus will be the first and only Chimeric Antigen Receptor T-cell therapy for this population of patients who have limited treatment options. Half of adults with ALL will relapse, and median overall survival for this group is only approximately eight months with current standard-of-care treatments. Following this positive opinion, the European Commission will now review the CHMP opinion; the final decision on the Marketing Authorization is expected in the coming months. Results from the ZUMA-3 international multicenter, single-arm, open-label, registrational Phase 1/2 study of adult patients with relapsed or refractory ALL, demonstrated that 71% of the evaluable patients achieved complete remission or CR with incomplete hematological recovery with a median follow-up of 26.8 months. In an extended data set of all patients dosed with the pivotal dose the median overall survival for all patients was more than two years and almost four years for responders. Among efficacy-evaluable patients, median duration of remission was 18.6 months. Among the patients treated with Tecartus at the target dose, Grade 3 or higher cytokine release syndrome and neurologic events occurred in 25% and 32% of patients, respectively, and were generally well-managed.

09:18 EDT Verizon says 'no noticeable change' in customer payment patterns - Seeing "strong payment patterns" from quality customer base. Expects "small bubble in churn" in Q3 due to pricing actions. "Feels really good" about overall long-term company strategy.

09:03 EDT Gevo signs fuel sales agreement with American for 100M gallons per year - Gevo (GEVO) announces a new fuel sales agreement with American Airlines (AAL). The agreement sets forth the terms for the sale of 100M gallons per year of sustainable aviation fuel for five years from Gevo's future commercial operations. Gevo's delivery of SAF under this agreement is expected to begin in 2026. Gevo estimates that the agreement should generate approximately $2.75 billion of revenue over the five-year term, inclusive of the value of environmental benefits. The Agreement with American Airlines is the single, largest fuel sales agreement ever entered into by Gevo with a customer. "The expansion of the global development of the SAF marketplace has reached an exciting point," said Dr. Patrick Gruber, Gevo's Chief Executive Officer. "While there is a tremendous amount of work to complete to bring all the critical elements of net-zero carbon SAF to the marketplace, our memoranda of understanding with oneworld alliance members and this subsequent commitment from American Airlines demonstrates the important momentum that is building for these types of products. I'm thrilled that Gevo is poised to continue to provide leadership for this product development." The agreement with American Airlines is subject to certain conditions precedent, including Gevo developing, financing, constructing and operating one or more production facilities to produce the SAF contemplated by the agreement. A copy of the agreement between American Airlines and Gevo will be filed with the U.S. Securities and Exchange Commission on Form 8-K no later than Friday, July 22, 2022.

08:51 EDT Verizon seeing inflation 'most notably' in transportation, wages, utilities - Expects inflation to impact profit in 2H22. Says Tracfone integration remains 'on track.'

08:44 EDT Altisource Asset Management announces repurchase of common stock - Altisource Asset Management Corporation announced that it purchased 286,873 shares of its common stock from Putnam Focused Equity Fund, a series of Putnam Funds Trust, at $10 per share.

08:43 EDT Rhythm Pharmaceuticals receives positive CHMP opinion for IMCIVREE - Rhythm Pharmaceuticals announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending to expand the current marketing authorization for IMCIVREE to include the treatment of obesity and control of hunger in adult and pediatric patients 6 years of age and older with genetically confirmed Bardet-Biedl syndrome. The CHMP opinion will now be reviewed by the European Commission, which has the authority to grant and expand marketing authorizations for medicinal products in the European Union. A final decision on the application to expand the marketing authorization for setmelanotide is anticipated in the fourth quarter of 2022.

08:38 EDT Rocky Mountain Chocolate reaffirms offer to settle proxy fight with AB Value - Rocky Mountain Chocolate publicly reaffirmed its settlement offer, originally made privately to AB Value two weeks ago, and requests that the AB Value and Bradley Radoff group act in the best interests of all stockholders by accepting the board's offer to add AB Value's remaining, sole nominee to the board and ceasing its proxy fight, its third in four years. On July 9, the board proposed to AB Value a settlement offer that provides for an increase in the size of the board to seven directors; the appointment of one of AB Value's nominees to the board; a commitment to re-nominate that AB Value nominee in 2023; a $600,000 reimbursement of AB Value's expenses and AB Value's agreement to a customary standstill to not run another proxy contest in 2023 and to dismiss AB Value's lawsuit seemingly instigated in support of their 2021 proxy contest, which AB Value has made no attempt to pursue other than as a negotiating chip. On July 20, AB Value announced that they will now only seek the election of one nominee. In less than three months, AB Value has gone from a proxy access nomination of a single nominee, to six nominees, to a reduced slate of two nominees and now just one nominee. The company said, "AB Value's latest nominee change now makes the Board's prior settlement offer even more sensible and thus even more in the best interests of all stockholders. The Board's prior offer would result in their sole nominee being added to the Board. As to the proposed customary standstill provision preventing yet another AB Value proxy contest in 2023, the Board's proposal would result in three of the seven directors on the Board having been originally selected by AB Value, seemingly obviating the need for AB Value to run its fourth proxy contest in five years in 2023. Finally, the Board's offer has the benefit of retaining Mr. Seabert, who is an audit committee financial expert and a certified public accountant (CPA) with over three decades of experience in business management, finance and real estate development. He also brings to the recently elected directors the benefit of his five years of service on the Company's Board. AB Value's baseless attacks on Mr. Seabert, including the illogical suggestion that the Board's current nomination of Mr. Seabert is related to the former CEO who is not a director or officer of the Company, do not provide a basis for AB Value to continue to reject the Board's offer. The Board originally made the offer two weeks ago, partially to mitigate the Company's costs and avoid further disruption. AB Value's delay in accepting the offer has significantly undercut those goals, but the Board, in an effort to save further costs and end AB Value's disruptive proxy contest, is willing to reaffirm that offer at this time subject to a timely and acceptable approval by the Board of Mary Bradley's background and experience based on an interview with her, which the Board will determine as expeditiously as possible. Ms. Bradley is AB Value's sole remaining nominee."

08:36 EDT Rocky Mountain Chocolate reaffirms prior offer to settle proxy fight - The company said, "Rocky Mountain Chocolate Factory publicly reaffirms its good faith settlement offer, originally made privately to AB Value two weeks ago, and requests that the AB Value and Bradley Radoff group act in the best interests of all stockholders by accepting the Board's offer to add AB Value's remaining, sole nominee to the Board and ceasing its costly, disruptive proxy fight, its third in four years. On July 9, 2022, the Board proposed to AB Value a settlement offer that provides for: an increase in the size of the Board to seven directors; the appointment of one of AB Value's nominees to the Board; a commitment to re-nominate that AB Value nominee in 2023; a $600,000 reimbursement of AB Value's expenses; and AB Value's agreement to a customary standstill to not run another proxy contest in 2023 and to dismiss AB Value's lawsuit seemingly instigated in support of their 2021 proxy contest, which AB Value has made no attempt to pursue other than as a negotiating chip. On July 20, 2022, AB Value announced that they will now only seek the election of one nominee. In less than three months, AB Value has gone from a proxy access nomination of a single nominee, to six nominees, to a reduced slate of two nominees and now just one nominee. AB Value's latest nominee change now makes the Board's prior settlement offer even more sensible and thus even more in the best interests of all stockholders. The Board's prior offer would result in their sole nominee being added to the Board. As to the proposed customary standstill provision preventing yet another AB Value proxy contest in 2023, the Board's proposal would result in three of the seven directors on the Board having been originally selected by AB Value, seemingly obviating the need for AB Value to run its fourth proxy contest in five years in 2023. Finally, the Board's offer has the benefit of retaining Mr. Seabert, who is an audit committee financial expert and a certified public accountant with over three decades of experience in business management, finance and real estate development. He also brings to the recently elected directors the benefit of his five years of service on the Company's Board. AB Value's baseless attacks on Mr. Seabert, including the illogical suggestion that the Board's current nomination of Mr. Seabert is related to the former CEO who is not a director or officer of the Company, do not provide a basis for AB Value to continue to reject the Board's offer. The Board originally made the offer two weeks ago, partially to mitigate the Company's costs and avoid further disruption. AB Value's delay in accepting the offer has significantly undercut those goals, but the Board, in an effort to save further costs and end AB Value's disruptive proxy contest, is willing to reaffirm that offer at this time subject to a timely and acceptable approval by the Board of Mary Bradley's background and experience based on an interview with her, which the Board will determine as expeditiously as possible. Ms. Bradley is AB Value's sole remaining nominee."

08:33 EDT iRhythm gains FDA clearance for its clinically integrated ZEUS system - iRhythm Technologies (IRTC) announced it received FDA 510(k) clearance for its ZEUS System for the Zio Watch. Produced in partnership with Verily, an Alphabet (GOOG;GOOGL) precision health company, the ZEUS System combines deep learned algorithms with a proven and trusted cardiac arrhythmia service. The ZEUS System is the AI algorithm and solution component of the Zio Watch: a sensor-based wearable for noninvasive, clinical grade, long-term continuous monitoring for atrial fibrillation. Verily also received FDA 510(k) clearance for the Zio Watch. The Zio Watch with the ZEUS System is an integrated, prescription-based solution that addresses clinician workflows, care pathways and the patient experience. The cleared Zio Watch is a wrist-worn solution that not only detects AFib, but also characterizes the amount of AFib over time, thus aiding a clinician in diagnosis. "We are incredibly excited about this important milestone as we make progress in bringing a new monitoring platform to patients who can benefit from it. There is a clear need in the market today for a clinical grade, long-term and noninvasive monitoring solution," said Quentin Blackford, CEO and President of iRhythm. "iRhythm is focused on redefining the standard of care with earlier insight to predict and prevent disease, and the Zio Watch with ZEUS System provides clinicians a platform that has the potential to meaningfully improve patients' lives."

08:30 EDT VistaGen Therapeutics trading resumes

08:20 EDT Alnylam receives CHMP opinion recommending approval of vutrisiran - Alnylam announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has adopted an opinion recommending approval of vutrisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated, or hATTR, amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy. If approved by the European Commission, or EC, vutrisiran will be commercialized under the brand name Amvuttra as the first and only treatment option to demonstrate reversal in neuropathy impairment with subcutaneous administration once every three months.

08:14 EDT Moderna says CHMP adopts positive opinion for COVID-19 booster in adolescents - Moderna announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending a variation to the conditional marketing authorization to include a booster dose of Spikevax, the Company's COVID-19 vaccine, at the 50 microgram dose level for adolescents at least three months after completion of the primary series. The CHMP based this positive opinion on scientific evidence shared by the company, including comprehensive safety data. The administration of a booster dose of 50 microgram at least three months after administration of completion of the primary series is predicted to substantially increase the immune responses against variants of concern, including Omicron compared to pre-boost levels.

08:10 EDT PPG sees Q3 aggregate sales volumes flat to down low-single-digit percentage - Says customer order backlogs in both the automotive refinish and aerospace coatings businesses remained elevated. Says sales volumes were impacted by slower production activity due to severe COVID-19 restrictions in China. Says demand in most regions is expected to remain solid and supply chain disruptions should continue to ease. Comments taken from Q2 investor presentation slides.

08:08 EDT Gogo's nationwide 5G network construction halfway complete - Gogo Business Aviation's nationwide 5G network construction is halfway to completion with the 75th site now online. Gogo 5G remains on budget and on schedule to launch in the second half of 2022.

08:07 EDT Moderna announces CHMP recommendation for Spikevax CMA - Moderna announced that the European Medicines Agency's, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has adopted an opinion recommending a variation to the conditional marketing authorization, or CMA, to include a booster dose of Spikevax, the company's COVID-19 vaccine, at the 50 microgram dose level for adolescents at least three months after completion of the primary series.

08:06 EDT Twitter down over 4% at $37.79 after Q2 earnings

08:06 EDT Twitter maintains that termination of merger attempt by Musk is 'invalid' - The company states: "As announced on April 25, 2022, we entered into a merger agreement, pursuant to which Twitter agreed to be acquired by an entity wholly owned by Elon Musk, for $54.20 per share in cash. Upon completion of the transaction, Twitter will become a privately held company. On July 8, 2022, representatives of Mr. Musk delivered a notice purporting to terminate the merger agreement. Twitter believes that Mr. Musk's purported termination is invalid and wrongful, and the merger agreement remains in effect. On July 12, 2022, Twitter commenced litigation against Mr. Musk and certain of his affiliates to cause them to specifically perform their obligations under the merger agreement and consummate the closing in accordance with the terms of the merger agreement. On July 19, 2022, Twitter's request for an expedited trial was granted, and the trial is being scheduled for October 2022."

08:04 EDT I-MAB says first patient dosed in China in Phase 1 clinical trial of TJ-CD4B - I-Mab announced that the first patient in China has been treated with TJ-CD4B, also known as ABL111, a novel Claudin 18.2 x 4-1BB bispecific antibody, in a Phase 1 international multi-center clinical trial for patients with solid tumors, including gastric cancer, gastroesophageal junction carcinoma, esophageal adenocarcinoma, and pancreatic ductal carcinoma.

08:04 EDT VistaGen Therapeutics announces PALISADE-1 trial did not meet primary endpoint - VistaGen Therapeutics announced results from its PALISADE-1 Phase 3 clinical trial of PH94B for the acute treatment of anxiety in adults with social anxiety disorder. PH94B did not achieve its primary endpoint, as measured by change from baseline using the Subjective Units of Distress Scale, or SUDS, compared to placebo. Although the trial did not meet its primary endpoint, the tolerability profile of PH94B in PALISADE-1 was favorable and consistent with previously reported results from all other clinical trials. No severe or serious adverse events were reported for PH94B in prior clinical trials or in PALISADE-1. PALISADE-1 was a multi-center, randomized, double-blind, placebo-controlled, parallel design, Phase 3 clinical study in adults diagnosed with social anxiety disorder, or SAD. The study was designed to evaluate the efficacy, safety, and tolerability of the acute administration of PH94B to relieve symptoms of anxiety in adult patients with SAD during a simulated public speaking challenge, measured using the patient-reported SUDS. Prior to the public speaking challenge, the subjects were randomized to receive a single dose of PH94B or placebo. VistaGen has three drug candidates in its CNS pipeline, PH94B, PH10 and AV-101, with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of the company's drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date, and has therapeutic potential in multiple CNS markets.

08:03 EDT Twitter reports Q2 mDAU 237.8M, up 16.6% y/y - Average US mDAU was 41.5 million for Q2, up 14.7% compared to Q2 of the prior year. Average international mDAU was 196.3 million for Q2, up 17.0% compared to Q2 of the prior year.

08:02 EDT Vertex Pharmaceuticals plans to advance VX-548 into Phase 3 clinical trials - Vertex Pharmaceuticals announced that following the Phase 2 results earlier this year and having reached agreement on the design of the pivotal development program with the FDA, Vertex plans to advance the selective NaV1.8 inhibitor VX-548 into Phase 3 clinical trials in Q4. Vertex also intends to initiate a Phase 2 dose-ranging study of VX-548 in neuropathic pain by the end of this year. In addition, the FDA has granted VX-548 Breakthrough Therapy Designation for the treatment of moderate-to-severe acute pain. The Phase 3 program will include two randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of VX-548 for moderate to severe acute pain following bunionectomy or abdominoplasty surgery. Both studies will also include a hydrocodone bitartrate/acetaminophen treatment arm. A third, single-arm study will evaluate the safety and effectiveness of VX-548 for up to 14 days across multiple other types of moderate to severe acute pain.

08:01 EDT Conagra Brands raises quarterly dividend 5.6% to 33c per share - To be paid on September 1 to stockholders of record as of the close of business on August 3.

07:46 EDT LiveOne regains Nasdaq compliance - LiveOne announced that on July 21, it received a letter from the The Nasdaq Stock Market informing it that Nasdaq has confirmed that LiveOne has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5450(a)(1) and that LiveOne's common stock will continue to be listed on The Nasdaq Capital Market.

07:43 EDT Innovation Pharmaceuticals provides update on brilacidin program in OM - Innovation Pharmaceuticals provided an update on the Company's Brilacidin program in Oral Mucositis. Brilacidin, delivered as an oral rinse, was shown in Phase 2 clinical testing to reduce incidence, delay onset and decrease duration of severe OM in Head and Neck Cancer patients receiving chemoradiation. The Company and FDA have completed an End-of-Phase 2 meeting and agreed to an acceptable Phase 3 program. To assess current insurance programs and Brilacidin's overall commercialization potential in OM, the Company engaged separate consulting firms to analyze the provider and payer landscape -- specifically, the likelihood of clinicians to prescribe and insurers to reimburse a novel OM treatment, such as Brilacidin, should it eventually gain marketing approval. Results of this analysis are summarized below. Large Unmet Need: Oral Mucositis presents a significant socioeconomic cost to the healthcare system and to patients, as it can substantially impact quality of life, result in hospitalization, and lead to disruptions in anti-cancer therapy and poorer outcomes. Current standard of care treatment options are lacking because they only act as symptom management and do not decrease incidence of severe OM. Competitive Positioning: Brilacidin's oral sachet formulation was perceived as convenient and highly preferred by key opinion leaders in comparison to intravenous options, and KOLs are willing to prescribe Brilacidin for all HNC patients because the compound's preventative properties and ease of use as an oral rinse. Brilacidin has the potential to be a first-line product for prevention and treatment of SOM due to efficacy perceived as being highly clinically meaningful. Development Considerations: KOLs viewed the primary endpoint of reducing SOM incidence as favorable, though recommend additional secondary endpoints to promote greater uptake. Maximizing overall efficacy was identified as a higher KOL priority than the specific mechanism of action by which efficacy is achieved. Coverage Perspectives: Developing Brilacidin as a New Drug Application, via the 505(b)(1) pathway, significantly improves Brilacidin's commercialization prospects in the OM therapeutic area. OM products, such as MuGard, GelClair, Episil, and Caphosol, which were developed as devices and not drugs, have struggled to show clinical benefit, as they are primarily palliative in nature, and from a government payer perspective are not covered under Medicare Part D. Reimbursement Landscape: At least 2 approved drugs in all therapeutic drug classes must be made available under Medicare Part D, per USP Medicare Model Guidelines. The guidelines establish the framework that drive payer formularies. Given there are no approved drugs for OM in HNC, should Brilacidin be approved, it is highly likely it would be included in payer formularies as a pharmacy benefit. Commercial Opportunity: Annually, in the U.S., Brilacidin has the potential to address 52,000 OM patients in HNC, with potential future extension to 20,000 OM patients in Hematopoietic Stem Cell Transplantation, and 160,000 OM patients in all chemotherapy categories. Based on physician estimates of Brilacidin adoption and other pricing-based assumptions, forecasts of U.S. annual sales are $188 million for OM in HNC patients in 2030, with a potential additional upside of $106 million for OM in HSCT and $598 million for OM in all chemotherapy categories.

07:37 EDT Verizon reports Q2 Business wireless retail postpaid net additions 430,000 - Business reported 430,000 wireless retail postpaid net additions in second-quarter 2022, including 227,000 postpaid phone net additions. This was the third consecutive quarter that Business reported more than 200,000 postpaid phone net additions. Phone gross additions in Business increased nearly 30 percent year over year. Wireless retail postpaid churn was 1.37 percent in second-quarter 2022, and wireless retail postpaid phone churn was 1.07 percent. Business reported 88,000 fixed wireless net additions in second-quarter 2022.

07:36 EDT Verizon reports Q2 Broadband net additions 268,000 - Total broadband net additions of 268,000, including 256,000 fixed wireless net additions. Total broadband net additions increased 39,000 from first-quarter 2022, and fixed wireless net additions increased 62,000 from first-quarter 2022. 36,000 Fios Internet net additions.

07:35 EDT Verizon CFO says 'confident' in long-term strategy - "Although recent performance did not meet our expectations, we remain confident in our long-term strategy," said Verizon CFO Matt Ellis. "We believe that our assets position us well to generate long-term shareholder value."

07:33 EDT Roche says CHMP recommends EU approval of Vabysmo - Roche announced that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion recommending the approval of Vabysmo for the treatment of neovascular or "wet" age-related macular degeneration and visual impairment due to diabetic macular edema, or DME. Based on this recommendation, a final decision regarding the approval of Vabysmo is expected from the European Commission in the near future, the company said.

07:11 EDT Gilead announces CHMP recommendation for Veklury MA - Gilead announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Commission, or EC, adopted an opinion on the fulfillment of the last specific obligation and recommended the granting of Marketing Authorization, or MA, for Veklury that is no longer subject to specific obligations. Veklury was initially granted a conditional marketing authorization in July 2020 for the treatment of COVID-19 in adults and adolescents with pneumonia requiring supplemental oxygen. In December of 2021, the conditional authorization was expanded to include adults who do not require supplemental oxygen and are at increased risk of developing severe COVID-19. The EC will review the CHMP recommendation and, pending adoption, Veklury will be fully authorized for these patients with COVID-19.

07:09 EDT Nutriband registers new company branch in Ecuador - Nutriband announced the opening of its new branch in Quito, Ecuador. The Company plans to expand its product offering to the region through product registration and contract services. "This is a key step for Nutriband and our shareholders as it shows our commitment to expanding our offerings into new markets with a goal to continue to build our revenue opportunities and relationships," said Gareth Sheridan, CEO.

07:07 EDT Cleveland-Cliffs sees FY22 average selling price $1,410 per net ton - The company said, "Based on the current 2022 futures curve, which implies an average hot-rolled coil steel index price of $850 per net ton for the remainder of the year, the Company would expect its full-year 2022 average selling price to be approximately $1,410 per net ton. This incorporates the Company's expectation of substantial increases in fixed price contracts resetting on October 1, 2022."

07:01 EDT Versus Systems signs first television contract for team-focused channel - Versus Systems announced that it has signed its first contract in the Over-the-Top, OTT, streaming media and TV vertical - a significant milestone in the company's history and a cornerstone in the company's growth plan. Versus plans to bring its reward-based fan engagement technology to an OTT sports team-focused TV channel that is expected to launch in the fourth quarter of 2022. The multi-year agreement includes adding interactive and second-screen elements to shows and content connected to a new OTT channel that will launch in Q4 2022. "Television is the future of Versus Systems. Over the next two years, beginning with this OTT partnership that will launch in Q4, we're going to bring our patented fan engagement software to the multi-hundred billion dollar AVOD and SVOD television verticals. Sponsorships and advertising on streaming media is going to be more personalized, more contextual, and more rewarding than traditional linear broadcast TV ads could ever be" said Matthew Pierce, Founder and CEO of Versus Systems. "From Netflix's recent partnership with Microsoft, from Disney's upcoming AVOD service, to the Warner Bros-Discovery merger, and to the recent partnership between YouTube and Shopify - it's clear that content creators and distributors are eager to find new ways to create innovative, rewarding connections between audiences, brands, and the content that they love. That's where Versus is going to succeed. We're bringing our best-in-class in-venue fan engagement platform to fans at home."

06:53 EDT Schlumberger reports Q2 cash flow from operations $408M - Second-quarter cash from operations was $408M and reflected the build-up of working capital in line with the significant revenue growth. Working capital is expected to improve and, consequently, free cash flow generation will accelerate through the second half of the year, consistent with historical trends.

06:24 EDT Dr. Reddy's launches first-to-market OTC equivalent of Allegra-D 24 HR in U.S. - Dr. Reddy's Laboratories announced the first-to-market launch of over-the-counter Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets, USP, the store-brand equivalent of Allegra-D 24 HR in the U.S. market, as approved by the U.S. FDA. Allegra-D 24 HR had U.S. retail sales of approximately $45M as of May 2022 according to IRI.

06:04 EDT Hepsiburada CEO Murat Emirdag to step down, Nilhan Onal to succeed - Hepsiburada announced the appointment of Nilhan Onal as CEO of the company, effective January 1, 2023. Murat Emirdag has decided to step down from his CEO duties for personal reasons. He will continue to lead the company and ensure a transition to the new CEO until January 1, 2023. As of January 1, 2023, Emirdag will be a non-executive director of the company's board of directors. Nilhan Onal joins Hepsiburada from Amazon Europe (AMZN), where she spent the last seven years focused on business transformation and growth. In her last role, she also oversaw strategy, operations and technology for Amazon's European Fashion business, driving strong results.

05:16 EDT iQIYI enters strategic agreement with Poly Culture Group in Beijing - iQIYI announced on July 19 that it has reached a strategic agreement in Beijing with Poly Culture Group Corporation. As the corporation touches on many aspects of the entertainment content ecology and integrates both companies' online and offline resources, it helps accelerate innovation and growth across different products and operational paradigms, which will further contribute to the development of the cultural and entertainment content ecology in China. According to the agreement, the corporation between iQIYI and Poly Culture will focus on various areas, including the investment and production of films and television contents, live theatre production, arts and children's education, membership sharing and ticketing, location-based entertainment, cultural real estate, and joint development of virtual idols and other intellectual property derivatives.